All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1700+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Genentech's Susvimo (targeting VEGF-A) lands FDA approval for diabetic macular edema treatment
Monoclonal antibody fragment, diabetic macular edema - Read more

Supernus's Onapgo (apomorphine hydrochloride) injection receives FDA approval for motor fluctuations in advanced Parkinson's disease
Small molecule, Parkinson’s disease - Read more

THE GOOD
Business Development

Enveric Biosciences' subsidiary Akos Biosciences licenses cannabinoid compounds to Restoration Biologics for developing joint disease treatments in humans and animals
Small molecule, joint disease, cannabinoid - Read more

MITEM PHARMA acquires Flisint antimicrobial from Sanofi for treating rare Enterocytozoon bieneusi microsporidia infections
Small molecule, Enterocytozoon bieneusi microsporidia infections, infectious disease, antimicrobial - Read more

PRESENTED BY TLDR BIOTECH
What would do with 5,000+ meticulously tagged biotech & pharma data points?

Over the past year, TLDR Biotech has been collecting and categorizing industry news across approvals, clinical trials, fundraises, partnerships, M&A, politics & policy, and much much more.

Each data point is tagged by drug modality, disease indication, tech area, and even more specific categories. For example:

🔍 Need to track all small molecule fundraises across oncology?

📈 Want a curated list of recent cell therapy clinical trials updates (both the successes and failures)?

💡 Looking for trends in Alzheimer's and Parkinson's disease partnerships?

We’re leveraging this resource to build tailored reports and curated insights for select clients—and we’re opening up limited access to interested parties.

If you’re interested, send us an email [email protected] with the subject line “5K BIOTECH DATA” and we’ll chat further.*

*If you’ve received this newsletter as an email, just hit reply!

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials

Cumberland Pharmaceuticals touts positive Ph2 data for ifetroban (targeting TxA2, PGH2) in Duchenne muscular dystrophy heart disease
Small molecule, Duchenne muscular dystrophy heart disease - Read more

LEO Pharma's Anzupgo (JAK inhibitor) cream delivers positive Ph3 trial for adolescents with moderate-severe chronic hand eczema
Small molecule, chronic hand eczema - Read more

Invivyd's VYD2311 monoclonal antibody shows promise in Ph1/2 trial as COVID-19 prevention and treatment alternative to vaccination.
Monoclonal antibody, COVID-19, vaccine alternative - Read more

THE GOOD
Company Launches

German biotech Akribion Therapeutics launches with €8M seed funding to develop RNA-guided cell depletion technology
RNA, head & neck cancer, targeted delivery, nuclease - Read more

THE GOOD
Earnings & Finances

Regeneron announces first-ever quarterly dividend of $0.88 per share, starting March 2024, earlier than previously indicated
Big pharma earnings, dividend - Read more

Regeneron's cancer drug Libtayo (targeting PD-1) achieves blockbuster status with $1.22B annual sales, despite focus on Eylea HD concerns
Monoclonal antibody, carcinoma, cancer - Read more

Pfizer reports strong Q4 with $4.1B COVID product sales, signalling end to pandemic-related market volatility
Big pharma earnings, COVID-19 - Read more

Pfizer reports $63.6B revenue, awaits obesity drug data while exploring deals up to $15B, including potential Chinese partnerships
Big pharma earnings, obesity, chinese partnerships - Read more

THE GOOD
Fundraises

Auron Therapeutics $27M Series B, developing cell-state plasticity treatments for cancer and inflammatory diseases
Small molecule, cancer, inflammatory, protein degrader - Read more

Enveric Biosciences $5M public offering, developing neuroplastogenic therapeutics for anxiety, depression and addiction treatment
Small molecule, depression, anxiety disorder, neuropsychiatry - Read more

Tenaya Therapeutics receives $8M grant to fund clinical trials for heart disease gene therapy
Gene therapy, heart disease, AAV - Read more

Lactiga secures “multi-year, multi-million dollar” NIH grant, developing mucosal antibody therapy for immunodeficient patients
Antibody, secretory IgA (sIgA) mucosally-targeted replacement therapy, immunocompromised - Read more

Serina Therapeutics $5M second tranche investment, developing small molecule Parkinson’s hopeful leveraging a proprietary “drug optimization technology”
Small molecule, Parkinson’s disease, drug delivery - Read more

GH Research $150M public offering, following impressive mebufotenin (targeting serotonin receptors) Ph2 data in treatment resistant depression
Small molecule, treatment-resistant depression, bipolar disorder, pospartum depression, psychedelic - Read more

THE GOOD
Mergers & Acquisition

Jabil acquires pharmaceutical manufacturer Pii to expand healthcare capabilities and provide end-to-end supply chain solutions for drug companies
CDMO, manufacturing, supply chain - Read more

THE GOOD
Research

Scientists develop MANAscore algorithm to quickly predict cancer patients' response to immunotherapy, improving treatment decision-making
Therapy prediction, immunotherapy, cancer, therapeutic course decision making - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

Pfizer discontinues B7-H4-directed ADCB7H4V for advanced solid tumors after lackluster Ph1 trial, resulting in $1 billion impairment charge and a ruined blockbuster dream
Antibody-drug conjugate, solid tumor, cancer - Read more

THE BAD
Earnings & Finances

Merck halts Gardasil shipments to China until mid-2025 due to falling demand, with global sales dropping 18% in Q4 2024
Vaccine, human papillomavirus - Read more

Bavarian Nordic shares drop 10% after 2024 results and disappointing 2025 guidance, despite strong travel health growth
Vaccine manufacturing - Read more

THE BAD
Lawsuits

Johnson & Johnson seeks fast court ruling on rejected 340B rebate model before September IRA drug pricing compliance deadline.
Inflation reduction act, 340B drug pricing program - Read more

THE BAD
Layoffs

Turnstone Biologics begins the dreaded “strategic alternatives” search as it discontinues TIDAL-01 program and cuts workforce
Cell therapy, head & neck cancer, carcinoma, tumor-infiltrating lymphocyte (TIL) - Read more

Bristol Myers Squibb and Kyowa Kirin announce layoffs affecting 119 total employees across New Jersey locations in 2024
Big pharma, research & development - Read more

Valerio Therapeutics shutters US operations, and likely furloughing staff, as cash supply dwindles
DNA, DNA-decoy, solid tumor, cancer - Read more

THE BAD
Politics & Policy

RFK Jr.'s HHS Secretary nomination advances to full Senate vote after narrow Finance Committee approval, despite vaccine controversy concerns
Vaccine, anti-vax, HHS - Read more

THE UGLY
Politics & Policy

China adds Illumina to "unreliable entity list" in retaliation for U.S. tariffs, citing discrimination against Chinese companies
Genomic sequencing, next-generation sequencing, tariffs - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here